In this free webinar, learn about the rapidly evolving landscape of Alzheimer's disease therapy development and treatment. Attendees will gain insights into the key considerations for various platforms and strategies to incorporate biomarkers into their global clinical trials. The featured speakers will share examples of global clinical trial inclusion of biomarkers of interest. The speakers will also discuss how advances in Alzheimer's disease pathology and progression are being applied to accelerate therapeutic development for other dementias such as Lewy body dementia.
TORONTO, Oct. 7, 2024 /PRNewswire-PRWeb/ -- Globally, more than 20 million people are diagnosed with Alzheimer's disease. Researchers have made tremendous progress in understanding Alzheimer's disease pathology, resulting in a consensus on the biological definition of the disease. Novel blood-based biomarkers, such as pTau217 and Aβ 42/40, have also emerged.
Now, with the approval of Eisai and Biogen's LeqembiTM and Lilly's KisunlaTM, therapeutic development efforts by biopharma have been reinvigorated, and diagnostics are now enabled by available therapies. The shifting dynamics of therapeutic development in dementia and neurodegenerative disease treatment requires an understanding not only of the diseases themselves but also an understanding of the patient care continuum from diagnosis to treatment.
To fully realize the benefits of promising emerging biomarkers like Aβ 42/40 or pTau217, the global ecosystem for bringing these biomarkers into practical use in drug development and diagnostic environments must be considered.
In this webinar, the expert speakers discuss novel biomarkers relevant to Alzheimer's disease and other neurodegenerative diseases and explore various platforms that support these biomarkers across a range of regulatory environments. They will bring real-life examples featuring innovative solutions and ecosystem partnerships that must be considered with global Alzheimer's disease clinical trial approaches.
Register for this webinar to learn more about how a holistic understanding of the disease pathology of Alzheimer's disease, Lewy body dementia and more — in both diagnostics and drug development — can drive accelerated therapies to patients in need.
Join experts from Labcorp, Dr. Magali Dupont, Staff Scientist, Immunology; and Dr. Robert Martone, Scientific Discipline Director, Neurology, for the live webinar on Wednesday, October 23, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Operationalizing Innovative Biomarkers to Support Evolving Therapeutic and Diagnostic Landscape for Neurodegenerative Diseases.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article